Sentiment-Signal
23,5
Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Stammdaten
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
Unternehmen & Branche
| Name | Axsome Therapeutics, Inc. |
|---|---|
| Ticker | AXSM |
| CIK | 0001579428 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 9,40 Mrd. USD |
| Beta | 0,47 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 638,496,000 | -183,174,000 | -3.68 | 689,805,000 | 88,295,000 |
| 2025-09-30 | 10-Q | 170,992,000 | -47,229,000 | -0.94 | 669,250,000 | 73,727,000 |
| 2025-06-30 | 10-Q | 150,042,000 | -47,973,000 | -0.97 | 639,785,000 | 73,075,000 |
| 2025-03-31 | 10-Q | 121,463,000 | -59,413,000 | -1.22 | 596,671,000 | 53,205,000 |
| 2024-12-31 | 10-K | 385,693,000 | -287,216,000 | -5.99 | 568,498,000 | 57,015,000 |
| 2024-09-30 | 10-Q | 104,762,000 | -64,602,000 | -1.34 | 561,458,000 | 92,898,000 |
| 2024-06-30 | 10-Q | 87,166,000 | -79,345,000 | -1.67 | 548,226,000 | 102,852,000 |
| 2024-03-31 | 10-Q | 74,999,000 | -68,357,000 | -1.44 | 545,728,000 | 144,036,000 |
| 2023-12-31 | 10-K | 270,600,000 | -239,238,000 | -5.27 | 588,236,000 | 190,977,000 |
| 2023-09-30 | 10-Q | 57,794,000 | -62,199,000 | -1.32 | 600,857,000 | 269,508,000 |
| 2023-06-30 | 10-Q | 31,300,000 | -67,170,000 | -1.54 | 611,638,000 | 278,804,000 |
| 2023-03-31 | 10-Q | 94,576,000 | -11,218,000 | -0.26 | 389,179,000 | 111,812,000 |
| 2022-12-31 | 10-K | 0 | -187,134,000 | -4.60 | 331,476,000 | 109,556,000 |
| 2022-09-30 | 10-Q | 16,846,000 | -44,823,000 | -1.07 | 338,957,769 | 157,361,000 |
| 2022-06-30 | 10-Q | 8,820,000 | -41,439,000 | -1.06 | 180,559,096 | 15,199,000 |
| 2022-03-31 | 10-Q | -39,632,000 | -1.06 | 88,560,261 | 14,698,000 | |
| 2021-12-31 | 10-K | -130,403,000 | -3.47 | 87,785,058 | 15,631,000 | |
| 2021-09-30 | 10-Q | 0 | -34,882,677 | -0.93 | 116,598,522 | 42,717,844 |
| 2021-06-30 | 10-Q | 0 | -32,284,209 | -0.86 | 143,264,750 | 71,436,620 |
| 2021-03-31 | 10-Q | -29,259,970 | 166,903,840 | 96,293,199 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-22 | Maizel Ari | Officer, Chief Commercial Officer | Open Market Sale | -7,500 | 182.42 | -1,368,150.00 | -43,2% | |
| 2026-02-26 | Jacobson Mark L. | Officer, Chief Operating Officer | Open Market Sale | -35,378 | 161.88 | -5,726,990.64 | -180,7% | |
| 2026-02-02 | TABUTEAU HERRIOT | Director, Officer, 10% Owner, Chief Executive Officer | Open Market Sale | -32,410 | 185.60 | -6,015,296.00 | -189,8% | |
| 2026-01-22 | Pizzie Nick | Officer, Chief Financial Officer | Open Market Sale | -12,000 | 187.92 | -2,255,040.00 | -71,1% | |
| 2026-01-21 | Maizel Ari | Officer, Chief Commercial Officer | Open Market Sale | -7,500 | 184.44 | -1,383,300.00 | -43,6% | |
| 2026-01-07 | TABUTEAU HERRIOT | Director, Officer, 10% Owner, Chief Executive Officer | Open Market Sale | -31,261 | 170.38 | -5,326,249.18 | -168,0% | |
| 2026-01-06 | TABUTEAU HERRIOT | Director, Officer, 10% Owner, Chief Executive Officer | Open Market Sale | -29,450 | 172.33 | -5,075,118.50 | -160,1% | |
| 2026-01-05 | TABUTEAU HERRIOT | Director, Officer, 10% Owner, Chief Executive Officer | Open Market Sale | -78,703 | 171.28 | -13,480,249.84 | -425,2% | |
| 2025-12-04 | TABUTEAU HERRIOT | Director, Officer, 10% Owner, Chief Executive Officer | Open Market Sale | -10,558 | 148.18 | -1,564,484.44 | -49,4% | |
| 2025-12-03 | TABUTEAU HERRIOT | Director, Officer, 10% Owner, Chief Executive Officer | Open Market Sale | -20,163 | 146.94 | -2,962,751.22 | -93,5% | |
| 2025-12-02 | TABUTEAU HERRIOT | Director, Officer, 10% Owner, Chief Executive Officer | Open Market Sale | -49,252 | 144.59 | -7,121,346.68 | -224,6% | |
| 2025-11-05 | TABUTEAU HERRIOT | Director, Officer, 10% Owner, Chief Executive Officer | Open Market Sale | -21,775 | 134.49 | -2,928,519.75 | -92,4% | |
| 2025-11-04 | TABUTEAU HERRIOT | Director, Officer, 10% Owner, Chief Executive Officer | Open Market Sale | -50,459 | 133.79 | -6,750,909.61 | -213,0% | |
| 2025-11-03 | TABUTEAU HERRIOT | Director, Officer, 10% Owner, Chief Executive Officer | Open Market Sale | -91,705 | 132.34 | -12,136,239.70 | -382,8% | |
| 2025-10-08 | TABUTEAU HERRIOT | Director, Officer, 10% Owner, Chief Executive Officer | Open Market Sale | -12,774 | 118.84 | -1,518,062.16 | -47,9% | |
| 2025-10-07 | TABUTEAU HERRIOT | Director, Officer, 10% Owner, Chief Executive Officer | Open Market Sale | -13,390 | 118.77 | -1,590,330.30 | -50,2% | |
| 2025-10-06 | TABUTEAU HERRIOT | Director, Officer, 10% Owner, Chief Executive Officer | Open Market Sale | -19,220 | 120.17 | -2,309,667.40 | -72,9% | |
| 2025-09-22 | Jacobson Mark L. | Officer, Chief Operating Officer | Open Market Sale | -10,000 | 115.96 | -1,159,600.00 | -36,6% | |
| 2025-09-16 | Jacobson Mark L. | Officer, Chief Operating Officer | Open Market Sale | -40,000 | 114.23 | -4,569,200.00 | -144,1% | |
| 2025-09-16 | TABUTEAU HERRIOT | Director, Officer, 10% Owner, Chief Executive Officer | Open Market Sale | -19,719 | 114.19 | -2,251,712.61 | -71,0% | |
| 2025-09-16 | Jacobson Mark L. | Officer, Chief Operating Officer | Open Market Sale | -5,783 | 116.19 | -671,926.77 | -21,2% | |
| 2025-09-15 | TABUTEAU HERRIOT | Director, Officer, 10% Owner, Chief Executive Officer | Open Market Sale | -15,254 | 117.37 | -1,790,361.98 | -56,5% | |
| 2025-09-12 | TABUTEAU HERRIOT | Director, Officer, 10% Owner, Chief Executive Officer | Open Market Sale | -27,907 | 118.96 | -3,319,816.72 | -104,7% | |
| 2025-09-02 | JEFFS ROGER | Director | Open Market Sale | -13,464 | 123.68 | -1,665,227.52 | -52,5% | |
| 2025-08-29 | JEFFS ROGER | Director | Open Market Sale | -20,000 | 121.27 | -2,425,400.00 | -76,5% | |
| 2025-08-28 | JEFFS ROGER | Director | Open Market Sale | -20,000 | 121.60 | -2,432,000.00 | -76,7% | |
| 2025-08-27 | JEFFS ROGER | Director | Open Market Sale | -20,000 | 122.30 | -2,446,000.00 | -77,2% | |
| 2025-08-26 | JEFFS ROGER | Director | Open Market Sale | -20,000 | 120.03 | -2,400,600.00 | -75,7% | |
| 2025-08-22 | JEFFS ROGER | Director | Open Market Sale | -16,694 | 120.08 | -2,004,615.52 | -63,2% | |
| 2025-06-23 | Murdock Hunter R. | Officer, General Counsel | Open Market Sale | -6,014 | 100.12 | -602,121.68 | -19,0% | |
| 2025-06-20 | Murdock Hunter R. | Officer, General Counsel | Open Market Sale | -7,500 | 102.47 | -768,525.00 | -24,2% | |
| 2025-06-18 | Murdock Hunter R. | Officer, General Counsel | Open Market Sale | -7,500 | 100.90 | -756,750.00 | -23,9% | |
| 2025-06-17 | Murdock Hunter R. | Officer, General Counsel | Open Market Sale | -7,500 | 100.26 | -751,950.00 | -23,7% | |
| 2025-06-16 | Murdock Hunter R. | Officer, General Counsel | Open Market Sale | -7,500 | 102.42 | -768,150.00 | -24,2% | |
| 2025-06-09 | Jacobson Mark L. | Officer, Chief Operating Officer | Open Market Sale | -25,000 | 110.44 | -2,761,000.00 | -87,1% | |
| 2025-05-28 | Jacobson Mark L. | Officer, Chief Operating Officer | Open Market Sale | -20,000 | 103.45 | -2,069,000.00 | -65,3% | |
| 2025-05-27 | Jacobson Mark L. | Officer, Chief Operating Officer | Open Market Sale | -20,673 | 104.66 | -2,163,636.18 | -68,3% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.